121 related articles for article (PubMed ID: 12647984)
1. Fluoropyrimidine resistance in colon cancer.
Gorlick R; Banerjee D
Expert Rev Anticancer Ther; 2002 Aug; 2(4):409-16. PubMed ID: 12647984
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance in colon cancer.
Gorlick R; Bertino JR
Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of drug resistance.
Longley DB; Johnston PG
J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.
de Angelis PM; Fjell B; Kravik KL; Haug T; Tunheim SH; Reichelt W; Beigi M; Clausen OP; Galteland E; Stokke T
Int J Oncol; 2004 May; 24(5):1279-88. PubMed ID: 15067352
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy.
Clark JL; Berger SH; Mittelman A; Berger FG
Cancer Treat Rep; 1987 Mar; 71(3):261-5. PubMed ID: 3815393
[TBL] [Abstract][Full Text] [Related]
6. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.
De Angelis PM; Svendsrud DH; Kravik KL; Stokke T
Mol Cancer; 2006 May; 5():20. PubMed ID: 16709241
[TBL] [Abstract][Full Text] [Related]
7. Clinical resistance to antimetabolites.
Spears CP
Hematol Oncol Clin North Am; 1995 Apr; 9(2):397-413. PubMed ID: 7642470
[TBL] [Abstract][Full Text] [Related]
8. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
Xi Y; Formentini A; Nakajima G; Kornmann M; Ju J
Oncol Rep; 2008 Jan; 19(1):257-62. PubMed ID: 18097604
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells.
Akhdar H; Loyer P; Rauch C; Corlu A; Guillouzo A; Morel F
Eur J Cancer; 2009 Aug; 45(12):2219-27. PubMed ID: 19524433
[TBL] [Abstract][Full Text] [Related]
11. Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?
Prall F; Ostwald C; Schiffmann L; Barten M
Oncol Rep; 2007 Jul; 18(1):203-9. PubMed ID: 17549369
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance.
Shin YK; Yoo BC; Chang HJ; Jeon E; Hong SH; Jung MS; Lim SJ; Park JG
Cancer Res; 2005 Apr; 65(8):3162-70. PubMed ID: 15833846
[TBL] [Abstract][Full Text] [Related]
13. Overview of tumor cell chemoresistance mechanisms.
Gatti L; Zunino F
Methods Mol Med; 2005; 111():127-48. PubMed ID: 15911977
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
[TBL] [Abstract][Full Text] [Related]
15. Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients.
Hoshino S; Yamashita Y; Maekawa T; Shirakusa T
Cancer Chemother Pharmacol; 2005 Dec; 56(6):648-52. PubMed ID: 15959779
[TBL] [Abstract][Full Text] [Related]
16. Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer.
Inoue T; Hibi K; Nakayama G; Komatsu Y; Fukuoka T; Kodera Y; Ito K; Akiyama S; Nakao A
J Gastroenterol; 2005 Feb; 40(2):143-7. PubMed ID: 15770397
[TBL] [Abstract][Full Text] [Related]
17. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.
Van Geelen CM; de Vries EG; de Jong S
Drug Resist Updat; 2004 Dec; 7(6):345-58. PubMed ID: 15790545
[TBL] [Abstract][Full Text] [Related]
18. Overcoming drug resistance in patients with metastatic breast cancer.
Wong ST; Goodin S
Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949
[TBL] [Abstract][Full Text] [Related]
19. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
20. Cell death in response to antimetabolites directed at thymidylate synthase.
Barbour KW; Berger FG
Cancer Chemother Pharmacol; 2008 Feb; 61(2):189-201. PubMed ID: 17396263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
